SCHEMBL4537409

SCHEMBL4537409

O=Cc1ccc2c(c1)CCN2CCCOCc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEAD3 Q99594 2/20 0.43
MEN1 O00255 6/20 0.42
KMT2A Q03164 6/20 0.42
MAPT P10636 5/20 0.42
ALDH1A1 P00352 3/20 0.42
HPGD P15428 2/20 0.42
GAA P10253 1/20 0.42
KDM4E B2RXH2 4/20 0.41
RECQL P46063 3/20 0.41
APOBEC3A P31941 2/20 0.41
BLM P54132 2/20 0.41
APOBEC3G Q9HC16 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
ALPL P05186 1/20 0.41
ALPI P09923 1/20 0.41
ALPG P10696 1/20 0.41
MAPK1 P28482 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
ACHE P22303 3/20 0.39
AOC3 Q16853 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8778013 0.84 MEN1 (0.47) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL6468593 0.82 MEN1 (0.48) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL31186636 0.82 GRM5 (0.43) TEAD3MEN1KMT2AALDH1A1ACHE
SCHEMBL31186639 0.82 TEAD3 (0.40) TEAD3MEN1KMT2AMAPTALDH1A1
SCHEMBL4532583 0.81 ALDH1A1 (0.58) TEAD3MEN1KMT2AMAPTALDH1A1
SCHEMBL31186642 0.81 ALDH1A1 (0.58) TEAD3MEN1KMT2AMAPTALDH1A1
SCHEMBL4543357 0.81 TEAD3 (0.43) TEAD3MEN1KMT2AALDH1A1GAA
SCHEMBL4537574 0.81 TEAD3 (0.39) TEAD3MEN1KMT2AHPGDKDM4E
SCHEMBL526097 0.80 NOTUM (0.49) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL2547257 0.80 TDP1 (0.45) MEN1KMT2AMAPTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10239833-B2 Intermediates, their process and use in preparation of selective α1-adrenoceptor antagonists, Silodosin MANKIND PHARMA LTD. (IN) 2019-03-26 US disclosed
US-20180111901-A1 Novel Intermediates, their Process And Use In Preparation of Selective a1-Adrenoceptor Antagonists, Silodosin MANKIND PHARMA LTD. (IN) 2018-04-26 US disclosed
EP-2984070-B1 N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES MANKIND PHARMA LTD (IN) 2018-01-17 EP disclosed
US-9862681-B2 N-haloalkylindoline intermediates, their process and use in preparation of Silodosin and its derivatives MANKIND RESEARCH CENTRE (IN) 2018-01-09 US disclosed
US-20160046577-A1 N-Haloalkylindoline Intermediates, Their Process And Use In Preparation of Silodosin And its Derivatives MANKIND PHARMA LTD (IN) 2016-02-18 US disclosed
EP-2984070-A1 N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES Mankind Research Centre (IN) 2016-02-17 EP disclosed
WO-2014167507-A1 N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES MANKIND RESEARCH CENTRE (IN) 2014-10-16 WO disclosed
WO-2014118606-A2 A NOVEL PROCESS FOR THE PREPARATION OF SILODOSIN ALEMBIC PHARMACEUTICALS LIMITED (IN) 2014-08-07 WO disclosed
WO-2014118606-A2 A NOVEL PROCESS FOR THE PREPARATION OF SILODOSIN ALEMBIC PHARMACEUTICALS LIMITED (IN) 2014-08-07 WO disclosed
WO-2012062229-A1 A METHOD OF MANUFACTURING (-)-L-(3-HYDROXYPROPYL)-5-[(2R)-2-({2,2,2-TRIFLUOROETHOXY)- PHENOXYETHYL}AMINO)PROPYL]-2,3-DIHYDRO-LH-INDOLE-7-CARBOXAMIDE ZENTIVA, K.S. (CZ) 2012-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10239833-B2 Intermediates, their process and use in preparation of selective α1-adrenoceptor antagonists, Silodosin ADRA1D, ADRB1, ADRA1A TEAD3 1945/4885MEN1 2109/4885KMT2A 3333/4885
US-20160046577-A1 N-Haloalkylindoline Intermediates, Their Process And Use In Preparation of Silodosin And its Derivatives ADRA1D, ADRA1A, ADRB1 TEAD3 2830/4885MEN1 2015/4885KMT2A 3543/4885
US-20180111901-A1 Novel Intermediates, their Process And Use In Preparation of Selective a1-Adrenoceptor Antagonists, Silodosin ADRA1D, ADRA1A, ADRB1 TEAD3 2033/4885MEN1 1463/4885KMT2A 3310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.